Company: PSTV
Filing Date: 2025-06-20
Form Type: S-1/A
Source: 0001193125-25-142935
Chunk: 25

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-20
Form: S-1/A
Chunk 25
---
 |
|:------------------------------------------------------------------|:----|:--|------:|:--|
| Increase per share attributable to this offering                  |     | $ |  0.87 |   |
| As adjusted net tangible book value per share after this offering |     | $ | (0.57 | ) |
| Dilution per share to new investors                               |     | $ | (0.88 | ) |

The number of shares of common stock to be outstanding immediately after this offering in the table above is based on 16,999,626 shares outstanding as of March 31, 2025 and excludes, as of March 31, 2025:

| • |     | 1,230,272 shares of common stock issuable upon exercise of stock options outstanding under our equity incentive 
 plans, with a weighted-average exercise price of $3.79 per share;                                               |

| • |     | 7,668 shares of common stock reserved for future issuance under our 2015 New Employee Incentive Plan; |

| • |     | 1,219,497 shares of common stock reserved for future issuance under our 2020 Stock Incentive Plan; |

| • |     | 398 and 27,792 shares of common stock issuable upon conversion of 1,014 shares of Series B Convertible Preferred 
 Stock and 938 shares of Series C Preferred Stock, respectively; and                                              |

| • |     | 19,396,099 shares of common stock issuable upon exercise of pre-funded or zero strike price warrants to purchase 
 common stock; and                                                                                                |

| • |     | 115,310,549 shares of common stock warrants that can be exercised into 454,415,621 shares of common stock, with a 
 range of exercise prices of $1.32 to $1.98 per share.                                                             |

15

THE SELLING STOCKHOLDER This prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that have been and may be issued to Lincoln Park pursuant to the Purchase Agreement. We are filing the registration statement that includes this prospectus pursuant to the provisions of the Registration Rights Agreement, which we entered into with Lincoln Park on June 17, 2025, concurrently with our execution of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to sales by Lincoln Park of the shares of our common stock that have been and may be issued to Lincoln Park under the Purchase Agreement